2269:HKG
WuXi Biologics (Cayman) Inc
HK$48.20
arrow_downward
-0.90%(-0.44) 1D
Oct 16, 4:08:14 PM GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2269...
Open
HK$49.98
High
HK$50.85
Low
HK$45.82
Mkt. cap
198.43B
Avg. vol.
30.42M
Volume
55.18M
P/E ratio
34.48
52-wk high
HK$58.00
52-wk low
HK$28.48
EPS
HK$1.40
Shares outstanding
1.23B
No. of employees
15K
Open
HK$49.98
High
HK$50.85
Low
HK$45.82
Mkt. cap
198.43B
Avg. vol.
30.42M
Volume
55.18M
P/E ratio
34.48
52-wk high
HK$58.00
52-wk low
HK$28.48
EPS
HK$1.40
Shares outstanding
1.23B
No. of employees
15K
News stories
From web sources and news partners
marketscreener.com
·
10 minutes ago
S&P 500 Posts Weekly Drop as Technology Sector Declines Amid AI Concerns
The Motley Fool
·
9 minutes ago
Inflation Rose to 3.7% in September. Is It Time to Sell the S&P 500?
Investing.com
·
24 minutes ago
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.34%
MarketWatch
·
3 minutes ago
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About WuXi Biologics (Cayman) Inc